Results 221 to 230 of about 29,286 (231)

Phase 1 pharmacokinetic and drug‐interaction study of dasatinib in patients with advanced solid tumors

Cancer, 2010
Faye M Johnson, Shruti Agrawal, Howard Burris   +2 more
exaly  

Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells

Gynecologic Oncology, 2011
Deanna Teoh, William T Barry, Susan K Murphy   +2 more
exaly  

Dasatinib treatment for Philadelphia chromosome‐positive leukemias

Cancer, 2009
Hanna Jean Khoury, François Guilhot, Timothy P Hughes   +2 more
exaly  

The effects of dasatinib on IgE receptor–dependent activation and histamine release in human basophils

Blood, 2008
Michael Kneidinger, Anja Vales, Christian Baumgartner   +2 more
exaly  

Bortezomib enhances the therapeutic efficacy of dasatinib by promoting c-KIT internalization-induced apoptosis in gastrointestinal stromal tumor cells

Cancer Letters, 2015
Ying Dong, Jianjuan Ma, Xuexin He
exaly  

Dasatinib: A Review in Chronic Myeloid Leukaemia and Ph+ Acute Lymphoblastic Leukaemia

Drugs, 2016
exaly  

Dasatinib

Reactions Weekly, 2013
openaire   +1 more source

Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors

Annals of Oncology, 2016
T Karrison, Merrill S Kies, K J Cullen
exaly  

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial

Blood, 2007
Hagop Kantarjian, Nelson Hamerschlak, Philippe Rousselot   +2 more
exaly  

Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells

British Journal of Cancer, 2009
exaly